TARSUS PHARMACEUTICALS INC
TARSNASDAQ🏆 #1382 by market capUS Equity
$173.87▲ $5.04 (+2.90%)
Simulated price1h—
24h▲ 2.9%
7d—
14d—
30d—
1y—
🏦Market Cap
$2.97B
Small Cap
📈Revenue Growth (YoY)
+105.2%
High Growth
📊Gross Margin
93.3%
High
💵FCF Margin
14.3%
Healthy
⚖️P/S Ratio
4.9x
Fair
Otter Score
58
Weak
No chart data available for TARS.
Trading Snapshot
- Day Range
- $173.00 – $175.48
- 52-Week Range
- $47.21 – $85.25
- Volume
- $2.86B
- Avg Volume
- $3.77B
- Shares Outstanding
- 43.0M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $606M
- Last Q Revenue
- $144M
- P/E Ratio
- —
- P/S Ratio
- 4.9x
- EPS (TTM)
- $-1.08
- Dividend Yield
- —
Why Investors Own TARS
- ✓High-growth profile — revenue up +45.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 39% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$606M▲ +41.9% YoY
Gross Margin (TTM)
38.7%▼ −0.2% YoY
Operating Income (TTM)
$106M▲ +41.9% YoY
Free Cash Flow (TTM)
$42M▲ +41.9% YoY
About TARSUS PHARMACEUTICALS INC
A company profile for TARSUS PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
58/100
Analyst Price Target
ⓘAverage Target
$205.88
▲ +18.4% Upside
High Target$249.25
Low Target$179.00
Based on 10 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
TARSUS PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift TARS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
TARSUS PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.